Artur Katz

1.5k total citations
59 papers, 998 citations indexed

About

Artur Katz is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Artur Katz has authored 59 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Oncology, 27 papers in Pulmonary and Respiratory Medicine and 23 papers in Cancer Research. Recurrent topics in Artur Katz's work include Breast Cancer Treatment Studies (15 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Treatments and Mutations (11 papers). Artur Katz is often cited by papers focused on Breast Cancer Treatment Studies (15 papers), Cancer Treatment and Pharmacology (12 papers) and Lung Cancer Treatments and Mutations (11 papers). Artur Katz collaborates with scholars based in Brazil, United States and Belgium. Artur Katz's co-authors include Everardo D. Saad, Marc Buyse, Paulo M. Hoff, Andrea Kazumi Shimada, Peggy L. Porter, Lajos Pusztai, Aknar Calabrich, Sérgio D. Simon, Rene Claúdio Gansl and Giuseppe Curigliano and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Cancer.

In The Last Decade

Artur Katz

56 papers receiving 972 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Artur Katz Brazil 15 604 360 326 204 135 59 998
Fotios Siannis United Kingdom 17 659 1.1× 513 1.4× 252 0.8× 305 1.5× 178 1.3× 22 1.5k
Martha Donoghue United States 16 696 1.2× 400 1.1× 285 0.9× 247 1.2× 163 1.2× 27 1.2k
C.J. Twelves United Kingdom 21 746 1.2× 264 0.7× 219 0.7× 89 0.4× 83 0.6× 55 987
Gisela Schwab United States 13 644 1.1× 352 1.0× 126 0.4× 361 1.8× 76 0.6× 23 1.3k
Pallavi S. Mishra‐Kalyani United States 22 883 1.5× 560 1.6× 191 0.6× 332 1.6× 91 0.7× 49 1.5k
Shakun Malik United States 18 454 0.8× 455 1.3× 259 0.8× 316 1.5× 97 0.7× 35 993
Robert H. El-Maraghi Canada 10 622 1.0× 256 0.7× 289 0.9× 121 0.6× 33 0.2× 22 848
Meredith K. Chuk United States 14 429 0.7× 260 0.7× 116 0.4× 175 0.9× 69 0.5× 29 858
Sirisha L. Mushti United States 11 697 1.2× 312 0.9× 135 0.4× 150 0.7× 81 0.6× 16 927
Geoffrey Kim United States 18 621 1.0× 354 1.0× 142 0.4× 205 1.0× 61 0.5× 29 1.0k

Countries citing papers authored by Artur Katz

Since Specialization
Citations

This map shows the geographic impact of Artur Katz's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Artur Katz with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Artur Katz more than expected).

Fields of papers citing papers by Artur Katz

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Artur Katz. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Artur Katz. The network helps show where Artur Katz may publish in the future.

Co-authorship network of co-authors of Artur Katz

This figure shows the co-authorship network connecting the top 25 collaborators of Artur Katz. A scholar is included among the top collaborators of Artur Katz based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Artur Katz. Artur Katz is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Asprino, Paula Fontes, Pedro A. F. Galante, Denis L. Jardim, et al.. (2023). The Clinical and Molecular Profile of Lung Cancer Patients Harboring the TP53 R337H Germline Variant in a Brazilian Cancer Center: The Possible Mechanism of Carcinogenesis. International Journal of Molecular Sciences. 24(20). 15035–15035. 3 indexed citations
2.
Cruz, Marcelo, Romualdo Barroso‐Sousa, Marina Sahade, et al.. (2023). Real-world treatment outcomes in HR+ HER2- metastatic breast cancer patients treated with CDK4/6 inhibitors: Results from a reference center in Brazil. Cancer Treatment and Research Communications. 35. 100683–100683. 11 indexed citations
3.
Alessi, Joao V., et al.. (2022). Unique SLC12A2-ROS1 fusion is associated with marked response to crizotinib in lung adenocarcinoma. SHILAP Revista de lepidopterología. 10. 2050313X221100407–2050313X221100407.
4.
Harada, Guilherme, et al.. (2022). Cardiovascular toxicity following immune checkpoint inhibitors: A systematic review and meta-analysis. Translational Oncology. 19. 101383–101383. 10 indexed citations
5.
Knebel, Franciele Hinterholz, Fabiana Bettoni, Joao V. Alessi, et al.. (2021). Impressive response to dabrafenib, trametinib, and osimertinib in a metastatic EGFR-mutant/BRAF V600E lung adenocarcinoma patient. npj Precision Oncology. 5(1). 5–5. 31 indexed citations
6.
Sandoval, Renata Lazari, Cibele Masotti, Mariana Petaccia de Macêdo, et al.. (2021). Identification of theTP53p.R337H Variant in Tumor Genomic Profiling Should Prompt Consideration of Germline Testing for Li-Fraumeni Syndrome. JCO Global Oncology. 7(7). 1141–1150. 9 indexed citations
7.
Harada, Guilherme, et al.. (2020). COVID-19 in a Patient with Advanced Merkel Cell Carcinoma Receiving Immunotherapy. Immunotherapy. 12(15). 1133–1138. 6 indexed citations
8.
9.
Alessi, Joao V., et al.. (2019). Alectinib activity in chemotherapy-refractory metastatic RET-rearranged non-small cell lung carcinomas: A case series. Lung Cancer. 139. 9–12. 14 indexed citations
10.
Markopoulos, Christos, David M. Hyams, Henry Gómez, et al.. (2019). Multigene assays in early breast cancer: Insights from recent phase 3 studies. European Journal of Surgical Oncology. 46(4). 656–666. 20 indexed citations
11.
Araujo, Luiz H., Clarissa Baldotto, Gilberto de Castro, et al.. (2018). Lung cancer in Brazil. Jornal Brasileiro de Pneumologia. 44(1). 55–64. 64 indexed citations
12.
Hyams, David M., Eric R. Schuur, Enrique Bargalló‐Rocha, et al.. (2017). Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays. Journal of Surgical Oncology. 115(6). 647–662. 10 indexed citations
13.
Fernandes, Gustavo dos Santos, Daniel M. Girardi, Maria Ignez Braghiroli, et al.. (2017). Next-generation Sequencing-based genomic profiling: Fostering innovation in cancer care?. Clinics. 72(10). 588–594. 2 indexed citations
14.
Hanna, Samir Abdallah, et al.. (2017). Radiotherapy for a breast cancer patient with Schnitzler syndrome: Report of acute toxicity and early follow-up. Reports of Practical Oncology & Radiotherapy. 22(6). 463–469. 1 indexed citations
15.
Sawamura, Márcio Valente Yamada, et al.. (2017). Acquired Pulmonary Arteriovenous Fistula within Metastasis from Choriocarcinoma: A Case Report. Case Reports in Oncology. 10(2). 671–675. 3 indexed citations
16.
Knebel, Franciele Hinterholz, Fabiana Bettoni, Andrea Kazumi Shimada, et al.. (2017). Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC. Lung Cancer. 108. 238–241. 63 indexed citations
17.
Jardim, Denis L., et al.. (2012). Bevacizumab as First-Line Therapy in Advanced Non-Small-Cell Lung Cancer. Drugs in R&D. 12(4). 207–216. 5 indexed citations
18.
Saad, Everardo D., et al.. (2012). Assessment of quality of life in advanced non-small-cell lung cancer: An overview of recent randomized trials. Cancer Treatment Reviews. 38(6). 807–814. 18 indexed citations
19.
Katz, Artur, et al.. (2009). Complete Radiologic Response in an Anaplastic Oligodendroglioma Treated with Temozolomide and Bevacizumab. Case Reports in Oncology. 2(1). 57–60. 1 indexed citations
20.
Katz, Artur, Rene Claúdio Gansl, Sérgio D. Simon, et al.. (1991). Phase II Trial of Etoposide (V), Adriamycin (A), and Cisplatinum (P) in Patients with Metastatic Gastric Cancer. American Journal of Clinical Oncology. 14(4). 357–358. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Fotios Siannis Breakdown of academic impact, for papers by Martha Donoghue Breakdown of academic impact, for papers by C.J. Twelves Breakdown of academic impact, for papers by Gisela Schwab Breakdown of academic impact, for papers by Pallavi S. Mishra‐Kalyani Breakdown of academic impact, for papers by Shakun Malik Breakdown of academic impact, for papers by Robert H. El-Maraghi Breakdown of academic impact, for papers by Meredith K. Chuk Breakdown of academic impact, for papers by Sirisha L. Mushti Breakdown of academic impact, for papers by Geoffrey Kim
Rankless by CCL
2026